A 2026 systematic review examined whether topical capsaicin — the compound responsible for the pungency of chili peppers — has measurable benefit for jaw pain, facial pain, or a persistent burning sensation in the mouth, with mixed results. Only the low-concentration (under 1%) formulation is available without a prescription; the high-concentration (8%) patch discussed later in this article requires in-office clinical administration.
Key Points
- A 2026 systematic review and meta-analysis pooled 9 studies (164 total participants) testing capsaicin for orofacial pain conditions including TMJ/TMD, burning mouth syndrome, trigeminal neuralgia, and neuropathic facial pain ([PMID 42653103]).
- These 164 participants are distributed across four distinct diagnostic subgroups (TMD, burning mouth syndrome, trigeminal neuralgia, and other neuropathic facial pain), so each individual condition — including burning mouth syndrome — is represented by a small number of trials and participants.
- Placebo-controlled trials showed only a non-significant trend toward pain reduction; uncontrolled before-after studies showed significant reduction — a gap that raises concerns about bias and expectancy effects, not confidence in efficacy.
- Burning mouth syndrome had the most internally consistent evidence among the conditions studied; TMJ/TMD evidence was inconsistent and not statistically significant.
- Adverse events (chiefly burning/irritation) were significantly more common with capsaicin than placebo (an odds ratio, not a direct risk multiplier, and based on a small number of events), though reported as mild and self-limited.
- This is not a new therapy — low-concentration topical capsaicin for TMJ pain has been studied since at least 2000 ([Winocur et al.] Orofacial Pain reference text); the new review simply consolidates and stress-tests that older evidence.
What is capsaicin, and why would it help facial pain?
Capsaicin is the compound that produces the sensation of heat in chili peppers. Applied to skin or mucosa, it binds to a nerve receptor called TRPV1, which normally responds to heat and chemical irritants. Sustained activation of TRPV1 produces a reversible functional and structural change in the treated nerve fibers — commonly described as defunctionalization, along with a reduction in epidermal nerve fiber density at the application site — which is the mechanism most consistently proposed in current pharmacology for capsaicin’s effects on neuropathic pain signaling ([Bell’s Oral and Facial Pain reference text]). Older explanations attributed this effect primarily to depletion of substance P, a neuropeptide involved in pain transmission; this may still play a contributing role but is now regarded as a simplification of the underlying TRPV1-mediated process.
This TRPV1-mediated mechanism is the rationale most often cited for capsaicin’s use in conditions considered primarily neuropathic, such as burning mouth syndrome and trigeminal neuralgia. TMJ/TMD pain is generally understood differently — as nociceptive/inflammatory joint and muscle pain rather than a primary disorder of nerve signaling. Capsaicin’s use in TMD has instead been explored on a counter-irritant/topical analgesic rationale, using the same local TRPV1 desensitization to reduce pain perception, rather than as a treatment directed at joint pathology itself.
How are these conditions diagnosed?
Capsaicin isn’t a diagnosis — it’s a treatment considered after a diagnosis is made. The conditions studied in the review are identified through different pathways:
- TMJ/TMD is diagnosed clinically using standardized criteria (DC/TMD) that assess jaw movement, joint sounds, muscle tenderness, and pain location, sometimes supported by imaging.
- Burning mouth syndrome is a diagnosis of exclusion — a burning sensation in the mouth with a normal-appearing mucosa, made after ruling out nutritional deficiencies, hormonal changes, xerostomia, and other identifiable causes ([PMID 42618912]).
- Trigeminal neuralgia and other neuropathic facial pain are diagnosed based on characteristic pain patterns (brief, shock-like episodes along a nerve distribution, typically unilateral; a continuous-pain variant is also recognized per ICHD-3 classification) and neurologic evaluation.
The point of this new review is not diagnostic — it’s about what happens after diagnosis, when capsaicin is one of several topical options under consideration.
What did the new research actually find?
| Condition studied | What the evidence shows | Practical takeaway |
|---|---|---|
| Burning mouth syndrome | Most internally consistent results of the conditions reviewed (I² = 0%) ([PMID 42653103]) | The most internally consistent evidence among the conditions studied; consistency between trials does not by itself indicate a statistically significant treatment effect, and this subgroup reflects a small number of trials |
| TMJ / TMD pain | Heterogeneous results; did not reach statistical significance in placebo-controlled analyses ([PMID 42653103]) | Current controlled evidence does not support capsaicin as a reliable TMD treatment |
| Trigeminal neuralgia / neuropathic facial pain | Included in the pooled population; overall placebo-controlled effect was non-significant | Individual case reports exist ([Epstein & Marcoe, Oral Surg Oral Med Oral Pathol 1994]), but pooled controlled data does not confirm benefit |
The central finding worth sitting with: placebo-controlled trials showed only a non-significant trend (p = 0.08), while uncontrolled pre-post studies (no comparison group) showed a significant effect. When a treatment looks better without a control group than with one, that’s a signal to be cautious — it suggests some of the apparent benefit may come from expectation, natural fluctuation in symptoms, or study design rather than the drug itself.
Which treatment is right for me?
Capsaicin is not new to this field. Low-concentration topical capsaicin (under 1%) has been used for localized TMJ pain since earlier trials ([Winocur et al., J Orofac Pain 2000]), and clinical texts describe two general approaches:
| Formulation | Typical use | Time to relief | Duration | Key limitation |
|---|---|---|---|---|
| Low-concentration (<1%) topical | Applied 3–4 times daily | 1–2 weeks for arthritic-type pain; 2–4 weeks for neuralgic pain | Requires ongoing repeated application | Immediate burning sensation on application affects adherence and complicates study blinding |
| High-concentration (8%) patch | Single in-office application | Not specified in reviewed source | Up to ~12 weeks per application | Requires clinical administration; more pronounced local irritation |
Given the new review’s findings, capsaicin is best framed as one option among several topical and systemic strategies for orofacial pain — not a first-line or standalone therapy. Established options like topical NSAIDs have their own separate, mixed evidence base for TMJ degenerative pain ([Senye et al., topical NSAID reference text]), and the choice between them depends on the specific diagnosis, prior treatment response, and tolerance for the burning side effect that comes with capsaicin use.
When should I see a specialist?
Persistent jaw pain, facial pain, or an unexplained burning sensation in the mouth lasting more than a few weeks warrants an orofacial pain evaluation — particularly before self-administering an over-the-counter capsaicin product, since self-treatment without a diagnosis can delay identification of a treatable underlying cause. A specialist evaluation is especially appropriate if pain doesn’t fit a clear pattern, hasn’t responded to first-line measures, or is accompanied by other symptoms such as numbness, jaw locking, or sleep disruption.
For referring providers
The 2026 systematic review ([PMID 42653103], PROSPERO-registered) pooled 9 studies (n=164) across TMD, burning mouth syndrome, trigeminal neuralgia, and neuropathic facial pain. These 164 participants are divided across the four diagnostic subgroups, so individual condition-level analyses — including the burning mouth syndrome subgroup discussed below — are based on small numbers of studies and participants, which limits the precision of any condition-specific conclusion. Placebo-controlled pooled analysis was non-significant (p = 0.08, I² = 86%), while uncontrolled pre-post analyses reached significance — a discordance the authors flag as a limitation on interpretability, possibly reflecting publication bias or expectancy effects rather than a genuine treatment effect. Burning mouth syndrome subgroup analysis showed the lowest heterogeneity (I² = 0%) of the conditions studied, indicating consistency between the small number of available trials; this does not by itself establish a statistically significant or larger treatment effect for BMS relative to the other conditions. TMD data remained heterogeneous and non-significant. Adverse events were significantly more frequent with capsaicin than control (OR = 19.84 — an odds ratio, best interpreted cautiously given the likely small number of underlying events), though characterized as mild and self-limited (primarily local burning). Given the small overall sample size, its distribution across four separate condition subgroups, and the gap between controlled and uncontrolled findings, this evidence does not currently support capsaicin as a standard therapy for TMD, and supports only cautious, individualized consideration for burning mouth syndrome pending larger controlled trials.
References
- Capsaicin for Orofacial Pain Management: Systematic Review and Meta-Analysis. [PMID 42653103]
- Exploring the association between menopause and burning mouth syndrome: an updated review. [PMID 42618912]
- Winocur E, Gavish A, Halachmi M, Eli I, Gazit E. Topical application of capsaicin for the treatment of localized pain in the temporomandibular joint area. J Orofac Pain 2000;14:31–36.
- Epstein JB, Marcoe JH. Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia. Oral Surg Oral Med Oral Pathol 1994;77:135–140.
- Peppin JF, Pappagallo M. Capsaicinoids in the treatment of neuropathic pain: A review. Ther Adv Neurol Disord 2014;7:22–32.
- Senye M, et al. Topical nonsteroidal anti-inflammatory agents for temporomandibular joint degenerative pain (background reference text).
